Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

Proposed Collection Title: Loan Repayment Programs (LRPs), 0925–0361, expiration date 01/31/26, EXTENSION, Office of the Director (OD), National Institutes of Health (NIH).

Need and Use of Information Collection: The NIH makes available financial assistance, in the form of educational loan repayment, to M.D., Ph.D., Pharm.D., Psy.D., D.O., D.D.S., D.M.D., D.P.M., D.C., N.D., O.D., D.V.M, or equivalent doctoral degree holders who perform biomedical or behavioral research in NIH intramural laboratories or as extramural grantees or scientists funded by domestic non-profit organizations for a minimum of two years (three years for the General Research subcategory) in research areas supporting the mission and priorities of the NIH. The information proposed for collection will be used by the DLR to determine an applicant's eligibility for the program.

OMB approval is requested for 3 years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 20,802.

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent	Number of respondents	Number of responses per respondent	Average time per response (in hours)	Total annual burden hours
Initial Extramural Applicants	1,000	1	8	8,000
Renewal Extramural Applicants	1,000	1	8	8,000
Initial Intramural Applicants	20	1	8	160
Renewal Intramural Applicants	50	1	8	400
Recommenders	8,080	1	30/60	4,040
Institutional Contacts	2,000	1	5/60	167
NIH LRP Coordinators	70	1	30/60	35
Total	12,220	12,220		20,802

Dated: December 17, 2025.

Jon Lorsch,

Deputy Director for Extramural Research, National Institutes of Health.

[FR Doc. 2025–23774 Filed 12–22–25; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Macromolecular Structure and Function A Study Section, January 27, 2026, 09:00 a.m. to January 28, 2026, 07:00 p.m., National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 which was published in the **Federal Register** on November 25, 2025, 90 FR 53364 Doc 2025–21044.

This meeting is being amended to change the meeting start time to 10:00 a.m. The meeting is closed to the public.

Dated: December 18, 2025.

Sterlyn H. Gibson,

Program Specialist, Office of Federal Advisory Committee Policy.

[FR Doc. 2025–23690 Filed 12–22–25; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of an Exclusive Patent License: Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1, or TRAT1

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The *Eunice Kennedy Shriver* National Institute of Child Health and Human Development, an institute of the National Institutes of Health, United States Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patent applications listed in the **SUPPLEMENTARY INFORMATION** section of this notice to EnZeta Immunotherapies, Inc., a company located in Coral Gables, FL.

DATES: Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center, representing the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development, on or before January 7, 2026 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, and comments relating to the contemplated an Exclusive Patent License should be directed to: Geoffrey E. Ravilious, Ph.D., NCI Technology Transfer Center, Telephone: 240–276–6391; Email: *geoffrey.ravilious@nih.gov*.

SUPPLEMENTARY INFORMATION:

Intellectual Property

1. United States Provisional Patent Application No. 63/625,354 filed January 26, 2024, and entitled ''ENHANCED TUMOR REACTIVITY OF T CELLS LACKING SIT1, LAX1, OR TRAT1'' [HHS Reference No. E–004–2024–0–US–01];

2. International Patent Application No. PCT/US2025/013054 filed January 24, 2025, and entitled ''ENHANCED TUMOR REACTIVITY OF T CELLS LACKING SIT1, LAX1, OR TRAT1'' [HHS Reference No. E–004–2024–0–PC–01]; and

3. any and all other U.S. and ex-U.S. patents and patent applications claiming priority to any one of the foregoing, now or in the future.

The patent rights in these inventions have been assigned to the Government of the United States of America.

The prospective exclusive license territory may be worldwide and the field of use may be limited to the following:

''The use of the Licensed Patent Rights to develop, manufacture, distribute, sell and use T-cell-based therapeutics for the treatment of solid tumors, high-grade dysplasia and pre-neoplastic conditions.''